Analysis of one case of almolertinib-induced interstitial lung disease in a lung cancer patient

Published on Jun. 13, 2026Total Views: 96 times Total Downloads: 20 times Download Mobile

Author: FAN Xinxing ¹ LI Ling ² ZHENG Menying ²  BAI Juan ²

Affiliation: 1. Department of Western Pharmacy, Affiliated Hospital of Chengdu University, Chengdu 610081, China 2. Department of Oncology, Affiliated Hospital of Chengdu University, Chengdu 610081, China

Keywords: Almonertinib Interstitial lung disease Lung cancer Adverse drug reaction

DOI: 10.12173/j.issn.2097-4922.202601076

Reference: FAN Xinxing, LI Ling, ZHENG Menying, BAI Juan.Analysis of one case of almolertinib-induced interstitial lung disease in a lung cancer patient[J]. Yaoxue QianYan Zazhi, 2026, 30(5): 895 - 900. DOI: 10.12173/j.issn.2097-4922.202601076[Article in Chinese]  Copied

Abstract
Full-text
References

Abstract

This article reports a case of interstitial lung disease in a lung cancer patient during the use of almonertinib. After 85 days of oral almonertinib administration, the patient developed worsening cough accompanied by significant exertional dyspnea, and chest CT examination revealed interstitial changes in both lungs. Based on the patient’s medication history, clinical symptoms and imaging findings, it was considered to be an adverse drug reaction caused by almonertinib. Almonertinib was discontinued immediately, and the patient received symptomatic and supportive treatment including glucocorticoid therapy, anti-infective agents, antitussive and anti-asthmatic medications. The patient's clinical symptoms gradually improved. The patient was subsequently received 6 cycles of chemotherapy with pemetrexed combined with carboplatin. The targeted therapeutic regimen was adjusted to furmonertinib 80 mg orally once daily. The patient was followed up for 140 days of furmonertinib treatment, and no similar adverse reactions occurred, and no similar adverse reactions occurred. By applying the Naranjo's Assessment Scale and the WHO-UMC Causality Assessment Criteria, the adverse reaction was judged to be probably related to almonertinib. This case suggests that close monitoring of respiratory symptoms is essential during clinical administration of almonertinib. In cases of newly developed respiratory abnormalities, timely screening and early intervention should be implemented to improve patient prognosis. After recovery from almonertinib -induced interstitial lung disease, switching to another third-generation epidermal growth factor receptor-tyrosine kinase inhibitor for subsequent treatment may be cautiously considered upon comprehensive clinical evaluation.

Full-text

Please download the PDF version to read the full text: download

References

1. 中国临床肿瘤学会(CSCO)非小细胞肺癌专家委员会, 抗肿瘤药物安全管理专家委员会. 三代EGFR-TKI在EGFR突变NSCLC治疗中应用的专家共识(2022年版)[J]. 中国肺癌杂志, 2022, 25(9): 627-641. [Chinese Society of Clinical Oncology(CSCO) Non-small Cell Lung Cancer Committee, Anti-cancer Drug Safety Management(ASMC). Consensus on application of third-generation EGFR-TKI in EGFR mutated NSCLC(2022 version)[J].Chinese Journal Lung Cancer,2022,25(9):627-641.] DOI: 10.3779/j.issn.1009-3419.2022.101.47.

2. 中国抗癌协会肺癌专业委员会. EGFR-TKI不良反应管理专家共识[J]. 中国肺癌杂志, 2019, 22(2): 57-81. [Chinese Society of Lung Cancer,Chinese Anti-Cancer Association. EGFR-TKI ADR management Chinese expert consensus[J]. Chinese Journal Lung Cancer, 2019, 22(2):57-81.] DOI:10.3779/j.issn.1009-3419.2019.02.01.

3. Zhang XJ, Zhang M, Du XY, et al. Clinical efficacy and safety analysis of aumolertinib in real-world treatment of EGFR-mutated advanced non-small-cell lung cancer[J]. Front Pharmacol,2024,9(15): 1331138. DOI: 10.3389/fphar.2024.1331138.

4. 张利苹. 阿美替尼治疗EGFR突变阳性晚期肺腺癌的疗效、安全性及预后因素分析[D].郑州: 郑州大学, 2023. DOI:10.27466/d.cnki.gzzdu.2023.002022.

5. 许娟娟, 赵晶晶. 阿美替尼致间质性肺病1例[J]. 数理医药学志,2026,39(3):228-232. [Xu JJ, Zhao JJ.Aumolertinib-induced interstitial lung disease: a case report[J]. Journal of Mathematical Medicine, 2026,39(3):228-232. ] DOI: 10.12173/j.issn.1004-4337.202510024.

6. 李桃霞, 郭咸希, 陈莹. 阿美替尼靶向治疗致非小细胞肺癌患者间质性肺病1例[J]. 中国药师,2022, 25(11): 2000-2001. [Li TX, Guo XX, Chen Y. A case of interstitial lung disease in a non-small cell lung cancer patient treated with Ametinib targeted therapy[J]. China Pharmacist, 2022, 25(11): 2000-2001.] DOI:10.19962/j.cnki.issn1008-049X.2022.11.024.

7. 孙雪林, 杜娇, 谭琴, 等. 阿美替尼上市后不良反应分析[J]. 中国药物警戒, 2024, 21(6): 683-686. [Sun XL,Du J,Tan Q,et al.Analysis of post-marketing adverse reactions of ametinib[J].Chinese Journal of Pharmacovigi-lance,2024,21(6):683-686.] DOI: 10.19803/j.1672-8629.20240089.

8. Adhikari B, Dongol RM, Baral D, et al. Pemetrexed and interstitial lung disease[J]. Acta Oncol, 2016, 55(4): 521-522. DOI: 10.3109/0284186X.2015.1080859.

9. Li S, Huang ZF, Zhong XY, et al. The real-world safety profile of pemetrexed and platinum with or without pembrolizumab: insights from a comparative analysis of FAERS database[J]. BMC Cancer, 2025, 25(1): 767. DOI: 10.1186/s12885-025-14171-3.

10. Naranjo CA, Shear NH, Lanctót KL. Advances in the diagnosis of adverse drug reactions[J]. J Clin Pharmacol, 1992, 32(10): 897 904. DOI: 10.1002/j.1552-4604.1992.tb04635.x.

11. World Health Organization-Uppsala Monitoring Centre. The use of the WHO-UMC system for standardised case causality assessment[EB/OL]. [2026-05-12]. https://www.who.int/docs/default-source/medicines/pharmacovigilance/whocausality-asses sment.pdf.

12. 肖志敏, 顾岩. 抗肺癌药物相关间质性肺病的研究进展[J]. 中国肺癌杂志, 2025, 28(4): 309-318. [Xiao ZM, Gu Y. Research progress of anti-lung cancer drug-related interstitial lung disease[J]. Chinese Journal Lung Cancer, 2025, 28(4): 309-318.] DOI: 10.3779/j.issn.1009-3419.2025.106.11.

13. 杨升锡, 许均通, 屠文莲. 阿美替尼治疗晚期非小细胞肺癌研究进展[J]. 中国药物警戒, 2025, 22(2): 235-240. [Yang SX, Xu JT, Tu WL. Research progress in the treatment of advanced non-small cell lung cancer with aumonertinib[J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 235-240.] DOI:10.19803/j.1672-8629.20240491.

14. National Cancer Institute(NCI), Cancer Therapy Evaluation Program(CTEP). Common Terminology Criteria for Adverse Events (CTCAE) v5.0[EB/OL]. (2017-11-27) [2026-01-10]. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_50.

15. 抗肿瘤药物相关间质性肺病诊治专家共识专家委员会. 抗肿瘤药物相关间质性肺病诊治专家共识[J].中华肿瘤杂志, 2022, 44(7): 693-702. [Anticancer Drug-induced Interstitial Lung Disease Management Group. Expert consensus on the diagnosis and treatment of anticancer drug-induced interstitial lung disease[J]. Chinese Journal of Oncology, 2022, 44(7): 693-702.] DOI:10.3760/cma.j.cn112152-20220412-00244.

16. 中华医学会肿瘤学分会. 中华医学会肺癌临床诊疗指南(2025版)[J].中华医学杂志,2025,105(34):2918-2959. [Oncology Society of Chinese Medical Association.Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2025 edition)[J]. National Medical Journal of China, 2025, 105(34): 2918-2959.] DOI:10.3760/cma.j.cn112152-20250511-00215.

17. Li MSC, Lee KWC, Mok KKS, et al. Brief report: risk of recurrent interstitial lung disease from osimertinib versus erlotinib rechallenge after symptomatic osimertinib-induced interstitial lung disease[J]. JTO Clin Res Rep, 2024, 5(4):100648. DOI: 10.1016/j.jtocrr.2024.100648.

18. Le X, Yu Y, Zhao Y, et al. PL04. 07 FURTHER: a global, randomized study of Firmonertinib at two dose levels in TKI-naive, advanced NSCLC with EGFR PACC mutations[J]. J Thorac Oncol, 2024, 19(10): S5-S6.DOI:10.1016/j.jtho.2024.09.019.